-
公开(公告)号：US08883981B2
公开(公告)日：2014-11-11
申请号：US12829836
申请日：2010-07-02
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中所含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US08492526B2
公开(公告)日：2013-07-23
申请号：US13166487
申请日：2011-06-22
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： C07K16/00
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2893 , C07K2317/24 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 公开了一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中如Kabat等人所述，由EU指数表示的位置276和339处的氨基酸。 被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US20100150917A1
公开(公告)日：2010-06-17
申请号：US12573689
申请日：2009-10-05
申请人： Ryuzo UEDA , Kenya Shitara , Shiro Akinaga , Rinpei Niwa , Masamichi Koike
发明人： Ryuzo UEDA , Kenya Shitara , Shiro Akinaga , Rinpei Niwa , Masamichi Koike
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , Y02A50/41 , Y02A50/412
摘要： The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.
摘要翻译： 本发明涉及体内调节性T细胞的消耗方法，抑制调节性T细胞的IL-10产生活性的方法，通过调节性T细胞治疗病变状态的疾病的治疗方法及增强肿瘤的方法 其包括向患者施用特异性结合人CC趋化因子4（CCR4）或其抗体片段的单克隆抗体。
-
公开(公告)号：US20080095765A1
公开(公告)日：2008-04-24
申请号：US11730992
申请日：2007-04-05
申请人： Shigeru Ilda , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara , Masamichi Koike
发明人： Shigeru Ilda , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara , Masamichi Koike
IPC分类号： A61K39/395 , A61P37/08 , C07K16/00 , C12N1/21 , C12P21/00
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
摘要翻译： 本发明提供一种抗体组合物，其包含特异性结合人白细胞介素-5受体α链并在Fc区具有复合型N-糖苷连接的糖链的抗体分子，其中复合型N-糖苷连接的糖链具有 岩藻糖在糖链的还原端不与N-乙酰氨基葡萄糖结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。
-
75.发明授权Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3 有权治疗癌症的方法，包括给予神经节苷脂GD3特异性的人嵌合抗体公开(公告)号：US07045129B2
公开(公告)日：2006-05-16
申请号：US10166626
申请日：2002-06-12
IPC分类号： A61K39/395
CPC分类号： C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.
摘要翻译： 公开了人源化嵌合体抗体，包含人源化嵌合体抗体和药学上可接受的载体的药物组合物，以及治疗癌症的方法，其包括向患者施用药学上可接受量的人源化嵌合体抗体。
-
公开(公告)号：US06617160B1
公开(公告)日：2003-09-09
申请号：US09119014
申请日：1998-07-20
申请人： Kenya Shitara , Mikito Ito , Nobuo Hanai
发明人： Kenya Shitara , Mikito Ito , Nobuo Hanai
IPC分类号： C07K1624
CPC分类号： G01N33/74 , A61K38/00 , C07K16/2803 , G01N33/57407 , G01N33/6893
摘要： The present invention provides a monoclonal antibody which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and a monoclonal antibody which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogensis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid, arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
摘要翻译： 本发明提供了与人VEGF受体Flt-1和细胞表面上表达人VEGF受体Flt-1的细胞免疫反应的单克隆抗体和抑制人VEGF与人VEGF受体Flt-1结合的单克隆抗体 。 它还提供了诊断或治疗其异常血管生成状态如实体瘤的增殖或转移，类风湿关节炎，关节炎，糖尿病性视网膜病，早产儿视网膜病，牛皮癣等疾病进展的疾病的手段。
-
公开(公告)号：US06495666B2
公开(公告)日：2002-12-17
申请号：US09764304
申请日：2001-01-19
IPC分类号： C07K1400
CPC分类号： C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.
摘要翻译： 公开了人源化嵌合体抗体，包含人源化嵌合体抗体和药学上可接受的载体的药物组合物，以及治疗癌症的方法，其包括向患者施用药学上可接受量的人源化嵌合体抗体。
-
公开(公告)号：US5807548A
公开(公告)日：1998-09-15
申请号：US454683
申请日：1995-05-31
IPC分类号： A61K36/00 , A61K38/00 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K16/00 , C07K16/18 , C07K16/30 , C07K16/32 , C07K16/46 , C07K19/00 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/12 , C12N15/13 , C12N15/62 , C12P21/08 , C12R1/91 , A61K39/395
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/462 , A61K2039/505 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a process for its production and methods for its use are disclosed. The chimera antibody is produced without changing any amino acids of its mouse antibody variable region.
摘要翻译： 公开了人源化嵌合体抗体，其生产方法及其使用方法。 在不改变其小鼠抗体可变区的任何氨基酸的情况下产生嵌合体抗体。
-
公开(公告)号：US4892935A
公开(公告)日：1990-01-09
申请号：US70052
申请日：1987-07-06
申请人： Hajime Yoshida , Nobuo Hanai , Kenya Shitara
发明人： Hajime Yoshida , Nobuo Hanai , Kenya Shitara
IPC分类号： G01N33/574 , C07K16/30 , C12P21/08 , G01N33/577
CPC分类号： C07K16/3023 , Y10S530/806 , Y10S530/808 , Y10S530/828 , Y10S530/861
摘要： Monoclonal antibodies being capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma, and non-reactive with human small cell lung carcinoma and normal human lung cells, and recognizing glycoproteins as antigens. Hybridomas having the characteristics of cell line SLC-454 secrete such antibodies. Method of diagnosing human lung cancer and method of therapeutic treatment are described.
摘要翻译： 能够与人类鳞状细胞肺癌，肺腺癌和大细胞肺癌反应的单克隆抗体，与人类小细胞肺癌和正常人肺细胞无反应，识别糖蛋白为抗原。 具有细胞系SLC-454特征的杂交瘤分泌此类抗体。 描述了诊断人肺癌的方法和治疗方法。
-
-
-
-
-
-
-
-
搜索结果
79 条记录 (耗时 0.04 秒)
